intravenous solutions (IV) are used to administer water, sugar, and salt directly into the venous circulation of patients. Routine maintenance, fluid resuscitation, redistribution, and replacement, are all performed with IV solutions and electrolytes. Mixed solutions, intravenous drugs, and nutrition, and have all become common in modern therapies. The global intravenous solutions market growth is expected to propel as major players adopt inorganic growth approaches such as acquisitions and collaborations to extend their intravenous solutions portfolio. For instance, Laboratoire Aguettant SAS, based in France, and Baxter International Inc., in April 2015, announced a license and distribution agreement intended for the trace elements, that are vital micronutrients used during Parenteral Nutrition (PN) therapies.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1134
In 2019, the global intravenous solutions market was worth US$ 8,372.0 million, and it is expected to exhibit a CAGR of 6.1 % during the forecast period of 2019 – 2027.
The Global Intravenous Solutions Market is expected to grow during the forecast period due to an increase in product releases and regulatory approvals for intravenous solution injection.
Over the forecast period, the global intravenous solutions market is expected to grow due to the increase in regulatory approvals for intravenous solution injections. For instance, B. Braun Medical Inc, a B. Braun subsidiary, that specializes in pain management and infusion therapy, in 2015, announced that their 70 % Dextrose for Injection in a 2L flexible container had received approval from U.S. Food and Drugs Administration. The 70 % Dextrose for injection is an intravenous solution that is used to replenish calories and fluids.
The global intravenous solutions market is expected to grow during the forecast period due to the introduction of new intravenous solution injections for the treatment of several diseases such as dehydration and gastrointestinal diseases. For instance, Fresenius Kabi USA LLC, which offers medications and technologies for transfusion, clinical nutrition, and infusion, introduced Vecuronium Bromide for Injection in 2017, in the U.S. The drug is used to maintain neuromuscular blockade as well as paralysis.
Increased U.S. FDA recalls of IV products are expected to hinder the global intravenous solutions market growth during the forecast period. For instance, the U.S. Food and Drug Administration (FDA) recalled NEXIVA Closed IV Catheter System Dual Port 18GA 1.25 IN (BD Nexiva catheter) of Becton Dickinson &Company in August 2018 due to a needle tip shield/safety mechanism failure.
The global intravenous solutions market is divided into five regions: Asia Pacific, Africa, the Middle East, Europe, North America, and Latin America. Europe during the forecast period is expected to account for the largest share in the global intravenous solutions market, due to rising parenteral (intravenous) nutrition (PN) product releases. For instance, Baxter International Inc, a global leader in parental nutrition therapy, introduced NUMETA G13E 300 mL in 2016, in Europe. NUMETA G13E is the only ready-to-use parenteral (intravenous) nutrition (PN) product for preterm newborns (less than 37 weeks gestation age).
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1134
Asia Pacific intravenous solutions market is expected to grow rapidly, owing to the increased launches of technologically advanced intravenous solutions by major players. For instance, Eurolife Healthcare, a manufacturer as well as distributor of specialty infusion and pharmaceuticals, in June 2019 released two intravenous IV products in the Indian drug market namely Discport and Lifeport.
Major players operating in the global intravenous solutions market are Salius Pharma Private Limited, Amanta Healthcare, B. Braun Melsungen Ag, Vifor Pharma Management Limited, Grifols S.A., ICU Medical Inc, Baxter International Inc, Fresenius Kabi USA LLC, JW Life Science Corp, and Axa Parenterals Limited.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837